A Phase 3, Multicenter, Randomized, Double-Blind, Parallel-Arm, Placebo-Controlled Maintenance Study of Mirikizumab in Patients with Moderately to Severely Active Ulcerative Colitis” LUCENT 2 |
Ongoing |
Mirikizumab |
3 |
I6T-MC-AMBG |
KFSH-D |
A Phase 3, Multicenter, Randomized, Double-Blind, Parallel, Placebo-Controlled Induction Study of Mirikizumab in Conventional-Failed and Biologic-Failed Patients with Moderately to Severely Active Ulcerative Colitis - LUCENT 1 |
Ongoing |
Mirikizumab |
3 |
I6T-MC-AMAN |
KFSH-D |
A Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study of Oral Ozanimod as Maintenance Therapy for Moderately to Severely Active Crohn’s Disease |
Ongoing |
Ozanimod HCl |
3 |
RPC01-3203 |
KAUH-J |
A phase 3, multi-center, open-label, randomized study of oral ABL001 versus bosutinib in patients with Chronic Myelogenous Leukemia in chronic phase (CML-CP), previously treated with 2 or more tyrosine kinase inhibitors |
Ongoing |
ABL001 (asciminib) |
3 |
CABL001A2301 |
KFSH&RC-R |
"A Phase 3, Multicenter, Open-Label Extension Study to Evaluate the Long-Term Efficacy and Safety of Mirikizumab in Patients with Moderately to Severely Active Ulcerative Colitis LUCENT 3" |
Completed |
Mirikizumab |
3 |
I6T-MC-AMAP |
King Fahad Specialist Hospital (Dammam) |
A Phase 3, Multicenter, Open-Label Extension Study of Oral Ozanimod for Moderately to Severely Active Crohn’s Disease |
Ongoing |
Ozanimod HCl |
3 |
RPC01-3204 |
KAUH-J |
"A Phase 3, Multicenter, Double-blind, Randomized, Placebo-controlled Clinical Study to Evaluate the Safety and Efficacy of Ertugliflozin (MK-8835/PF-04971729) in Pediatric Participants (ages 10 to 17 years, inclusive) with Type 2 Diabetes Mellitus" |
Ongoing |
Ertugliflozin |
3 |
MK-8835-059-00 |
KSH |
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Multicenter Study To Determine The Efficacy And Safety Of Luspatercept (Ace-536) Versus Placebo In Adults Who Require Regular Red Blood Cell Transfusions Due To Beta -Thalassemia The “BELIEVE” Trial |
Completed |
Luspatercept (ACE 536) |
3 |
ACE-536-B-THAL-001 |
KKUH |
A Phase 3, Double-Blind, Randomized, Efficacy and Safety Comparison of Prasugrel and Placebo in Pediatric Patients With Sickle Cell Disease. |
Terminated |
Prasugrel |
3 |
H7T-MC-TADO |
KAUH-J |
A PHASE 2A, DOUBLE-BLIND, RANDOMIZED, PLACEBO-CONTROLLED, PARALLEL GROUP STUDY TO EVALUATE THE EFFICACY AND SAFETY OF ORAL PF-06651600 AND PF 06700841 AS INDUCTION AND OPEN LABEL EXTENSION TREATMENT IN SUBJECTS WITH MODERATE TO SEVERE CROHN’S DISEASE |
Completed |
PF-06651600 |
2a |
B7981007 |
NGHA-R,KKUH, King Abdulaziz Medical City NG (Jeddah) |